Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Rheumatology

The Standard of Care: Managing Your Treatment Plan

At a Glance

The goal of polymyositis treatment is achieving remission. Standard care involves a phased approach: high-dose corticosteroids quickly stop inflammation, steroid-sparing immunosuppressants provide long-term maintenance, and physical therapy rebuilds strength once the flare is controlled.

Navigating the treatment for polymyositis (PM) can feel like a marathon. While there is currently no “cure” that permanently erases the condition, the goal of modern medicine is to achieve remission—a state where inflammation is silenced, muscle enzymes normalize, and you regain your strength [1][2].

Because every person’s myositis is slightly different, your treatment plan will likely be a multi-layered “cocktail” of medications designed to both halt the attack and protect your body from long-term damage [3].

Phase 1: The Fire Extinguisher (Corticosteroids)

The first priority in treating PM is to stop active muscle damage as quickly as possible. High-dose corticosteroids, such as Prednisone, are the standard first-line treatment [4][5].

  • How they work: They act like a “fire extinguisher” for your immune system, rapidly cooling the inflammation that is attacking your muscle fibers [5].
  • The Taper: While effective, steroids carry significant risks if used at high doses for too long (such as bone loss, weight gain, and high blood sugar). Your doctor will create a tapering schedule to slowly lower your dose as your strength improves [5].

Phase 2: The Maintenance Crew (Steroid-Sparing Agents)

Because of the risks of long-term steroid use, doctors typically introduce steroid-sparing immunosuppressants early in the process—sometimes on the very same day you start Prednisone [3][6].

  • Methotrexate and Azathioprine: These are the most common “second-line” agents. They provide a steady, long-term way to keep the immune system in check [3].
  • Patience is Key: Unlike steroids, these medications do not work immediately. It often takes weeks to months for them to reach full efficacy, which is why they are started early.

Safety and Side Effects

It is vital to understand that immunosuppressants require careful monitoring [7]:

  • Infection Risk: By suppressing your immune system, you are at a higher risk for infections. Ask your doctor about required vaccinations before starting.
  • Monitoring: Both medications require frequent blood tests to monitor your liver function and blood counts.
  • Methotrexate Specifics: Methotrexate can cause severe birth defects, so strict pregnancy prevention is necessary. Additionally, it can cause liver toxicity, meaning patients must avoid alcohol while taking it [8]. Nausea is also a common side effect.

Phase 3: Advanced Options (Refractory Treatment)

If your strength does not improve or your muscle enzymes (CK) remain high despite steroids and maintenance drugs, your condition may be considered refractory [9]. At this point, your doctor may suggest advanced therapies:

  • Intravenous Immunoglobulin (IVIG): This involves infusions of antibodies from healthy donors to “neutralize” the harmful antibodies in your own blood [9].
  • Rituximab: A specialized biological drug that targets and removes the B-cells responsible for producing autoantibodies [9][10].

Physical Therapy: Timing is Everything

Physical therapy (PT) is a crucial part of recovery, but timing matters. During an active “flare” when muscles are actively inflamed, pushing yourself too hard can cause more damage. However, once the inflammation is controlled by medication, active PT is essential to rebuild lost muscle mass and regain function.

Tracking Your Remission

Your doctor will track “minimal, moderate, or major improvement” using composite response criteria—a combination of your CK levels, your own report of your fatigue, and a physical exam of your muscle strength [11]. Achieving a “drug-free remission” is the ultimate long-term goal, though many patients find that a small “maintenance dose” of medication is necessary to keep the disease in check for years to come [1].

Common questions in this guide

What is the first-line treatment for polymyositis?
High-dose corticosteroids, such as prednisone, are typically the first-line treatment. They act quickly to cool down your immune system and stop active muscle damage during a flare.
Why do I need to take immunosuppressants like methotrexate?
Doctors prescribe steroid-sparing immunosuppressants, like methotrexate or azathioprine, to provide long-term immune control without the severe side effects of prolonged steroid use. Because these drugs take weeks to months to work fully, they are often started at the same time as steroids.
What happens if standard polymyositis treatments do not work?
If your muscle enzymes remain high and your strength does not improve with standard medications, your condition may be considered refractory. At this stage, your doctor might recommend advanced therapies like Intravenous Immunoglobulin (IVIG) or a biologic drug called rituximab.
When is it safe to start physical therapy for polymyositis?
Active physical therapy should begin only after medication has controlled the active inflammation in your muscles. Pushing yourself too hard during an active disease flare can cause further muscle damage, so timing your therapy with your doctor is essential.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my target dose for Prednisone, and what is the planned timeline for tapering it down?
  2. 2.Which steroid-sparing agent (like Methotrexate or Azathioprine) is best suited for my specific case, and how often will I need bloodwork to monitor my liver?
  3. 3.Since my diagnosis is [insert subtype], should we consider advanced therapies like Rituximab or IVIG sooner rather than later?
  4. 4.What side effects should I be most concerned about with these immunosuppressants, and how will we screen for them?
  5. 5.When is it safe for me to begin active physical therapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Remission and low disease activity definitions in adult idiopathic inflammatory myopathies: A narrative review by myositis clinical trials consortium (MCTC).

    Pongtarakulpanit N, Keret S, Kothari V, et al.

    Autoimmunity reviews 2025; (24(10)):103879 doi:10.1016/j.autrev.2025.103879.

    PMID: 40669680
  2. 2

    Long-term outcomes of idiopathic inflammatory myopathies: a large-scale longitudinal cohort study.

    Chen Y, Zhu L, Zong C, et al.

    Journal of autoimmunity 2025; (154()):103435 doi:10.1016/j.jaut.2025.103435.

    PMID: 40334620
  3. 3

    Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.

    Ruperto N, Pistorio A, Oliveira S, et al.

    Lancet (London, England) 2016; (387(10019)):671-678 doi:10.1016/S0140-6736(15)01021-1.

    PMID: 26645190
  4. 4

    Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management.

    Leung AKC, Lam JM, Alobaida S, et al.

    Current pediatric reviews 2021; (17(4)):273-287 doi:10.2174/1573396317666210426105045.

    PMID: 33902423
  5. 5

    Dermatomyositis with exfoliation of esophageal mucosa: A case report.

    Zheng W, Zhang H, Zhang X, Liu Y

    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2021; (46(1)):104-107 doi:10.11817/j.issn.1672-7347.2021.190258.

    PMID: 33678644
  6. 6

    Interstitial Lung Disease in Polymyositis and Dermatomyositis.

    Long K, Danoff SK

    Clinics in chest medicine 2019; (40(3)):561-572 doi:10.1016/j.ccm.2019.05.004.

    PMID: 31376891
  7. 7

    Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected].

    Meyer A, Scirè CA, Talarico R, et al.

    RMD open 2018; (4(Suppl 1)):e000784 doi:10.1136/rmdopen-2018-000784.

    PMID: 30886730
  8. 8

    The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review.

    Caron AGM, Bloem M, El Khattabi H, et al.

    The Journal of dermatological treatment 2024; (35(1)):2292962 doi:10.1080/09546634.2023.2292962.

    PMID: 38124505
  9. 9

    Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.

    Zeng R, Glaubitz S, Schmidt J

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):911-921 doi:10.1007/s13311-022-01220-z.

    PMID: 35394612
  10. 10

    Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin.

    MacIsaac J, Siddiqui R, Jamula E, et al.

    Transfusion 2018; (58(11)):2729-2735 doi:10.1111/trf.14841.

    PMID: 30244480
  11. 11

    Update on outcome assessment in myositis.

    Rider LG, Aggarwal R, Machado PM, et al.

    Nature reviews. Rheumatology 2018; (14(5)):303-318 doi:10.1038/nrrheum.2018.33.

    PMID: 29651119

This page explains standard polymyositis treatment options for educational purposes only. Always consult your rheumatologist or healthcare provider before starting, stopping, or changing your medications.

Get notified when new evidence is published on Polymyositis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.